#FHTX

StockTitan

@stocktitan.net

3 days ago

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook Foghorn Therapeutics (Nasdaq: FHTX) provided a 2025 financial update and 2026 strategic outlook on March 11, 2026, reporting key pipeline progress and a strengthened balance sheet. Highlights: FHD-909 Phase 1 dose escalation is advancing; Selective CBP and EP300 degrader programs are tracking to IND-enabling studies in 2026. Collaboration revenue was $30.9M in 2025. Cash, cash equivalents, and marketable securities were $158.9M at year-end 2025, and a $50M registered direct financing in January 2026 extends runway into the first half of 2028.

#FHTX Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

2 months ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)

#FHTX Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

4 months ago

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+

#FHTX Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

4 months ago

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs Foghorn Therapeutics (NASDAQ: FHTX) reported preclinical progress for three selective degrader programs and will host a virtual investor event on October 30, 2025 at 12:00 p.m. ET. Key advances: a first-in-class Selective ARID1B degrader achieving selective degradation and downstream gene modulation with in vivo proof-of-concept targeted for 2026; a Selective CBP degrader (CBPd-171) entering non-GLP toxicology in Q4 2025 and targeting IND-readiness in 2026 with an optimized long-acting injectable; and a Selective EP300 degrader showing broad heme activity (>70% sub-lineages) and favorable tolerability in multiple myeloma models.

#FHTX Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

4 months ago

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit Foghorn Therapeutics (Nasdaq: FHTX) announced presentation and investor event updates on its targeted protein degrader programs. A Keynote Plenary presentation on the Selective ARID1B degrader will be delivered on Oct 29, 2025 at 3:45 p.m. EDT at the 8th Annual TPD and Induced Proximity Summit in Boston.Foghorn will host a virtual investor event on Oct 30, 2025 at 12 p.m. EDT to review pipeline updates for the Selective ARID1B, Selective CBP, and Selective EP300 degrader programs, including progress toward IND‑enabling studies. The presentation and replay will be available on the company website under Science and Events & Presentations.

#FHTX Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

7 months ago

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update Foghorn Therapeutics (Nasdaq: FHTX) released its Q2 2025 financial and corporate update, highlighting significant progress across its clinical pipeline. The company's lead program, FHD-909, a first-in-class SMARCA2 selective inhibitor targeting NSCLC, is progressing well in Phase 1 trials. Preclinical data showed synergistic benefits when combined with pembrolizumab and KRAS inhibitors.The company reported strong financial position with $198.7 million in cash and equivalents, extending runway into 2028. Q2 2025 saw collaboration revenue of $7.6 million and a reduced net loss of $17.9 million compared to $23.0 million in Q2 2024. Multiple pipeline developments are expected, including the advancement of their Selective CBP degrader program targeting IND in 2026, and updates on EP300 and ARID1B degrader programs in Q4 2025.

#FHTX Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

8 months ago

Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform Flagship Pioneering has unveiled Terrana Biosciences, a new agricultural technology company developing RNA-based solutions for crop enhancement and protection. The company emerges with an initial $50 million commitment from Flagship Pioneering after four years of platform development.Terrana's proprietary RNA technology platform enables the development of targeted products that can work throughout a plant's lifecycle, creating solutions that adapt to variable climate conditions. The company has already demonstrated proof of concept in tomatoes, corn, and soy, and generated a pipeline of over 15 potential products in specialty and row crops.The company's platform leverages AI and computational models to assemble a vast RNA library and design system for creating novel functional crop traits. Their solutions aim to help farmers combat diseases and pests, adapt to climate conditions, and maintain soil health, while offering advantages over conventional approaches in terms of timing flexibility and environmental impact.

#FHTX #MRNA #SANA Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

www.stocktitan.net/news/FHTX/flagship-pione...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with declining money flow, Wed Jun 4th - #SXTP #TCMD #SBGI #POWW #OCG #MBRX #LOOP #KGEI #HIFS #GALT #FHTX #CCRN #BTMD #PCG #HTH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

10 months ago

Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise Latest clinical trial data reveals progress in cancer drug development, while $220.6M cash position extends runway into 2027. See detailed pipeline updates.

#FHTX Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

10 months ago

Ted Myles Joins Cellarity as Chief Executive Officer Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.

#FHTX #MRNA #SANA Ted Myles Joins Cellarity as Chief Executive Officer

www.stocktitan.net/news/FHTX/ted-myles-join...

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

Small-cap stocks in new uptrend with average directional index, Wed Apr 23rd - #AREN #OKYO #GAUZ #VBTX #SIGA #RLMD #PESI #NEON #SNOA #JANX #IRIX #FHTX #EDIT #DRCT #CNCK #AMLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

11 months ago

Major Breakthrough: Pfizer Teams With Flagship to Develop AI-Driven Autoimmune Treatments Novel AI platform Logica powers new drug discovery collaboration, marking 6th partnership between pharma giant Pfizer and Flagship Pioneering. Full details inside.

#FHTX #MRNA #SANA Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

www.stocktitan.net/news/FHTX/flagship-pione...

StockTitan

@stocktitan.net

11 months ago

Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer New preclinical data shows FHD-909's enhanced efficacy when combined with standard treatments for NSCLC. Multiple promising programs advance. Full analysis inside.

#FHTX Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

1 year ago

Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science Lila Sciences, founded by Flagship Pioneering in 2023, has emerged with a groundbreaking scientific superintelligence platform and autonomous labs for life, chemical, and materials sciences. The company has secured $200 million in seed financing from multiple investors including Flagship Pioneering, General Catalyst, and ARK Venture Fund.The platform combines generative AI with autonomous AI science units to scale and optimize experimentation across scientific domains. Early achievements include developing advanced LLMs, generating optimal genetic medicine constructs, discovering novel antibodies, and creating cost-effective green hydrogen catalysts.Led by CEO Geoffrey von Maltzahn and a team of experts including Chief Scientist George Church and CTO Andrew Beam, Lila's platform will be available to partners in life and material sciences industries to accelerate solutions in human health and sustainability.

#FHTX #MRNA #SANA Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

www.stocktitan.net/news/FHTX/flagship-pione...

StockTitan

@stocktitan.net

1 year ago

Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates Clinical progress in SMARCA4 cancer program, extended cash runway to 2027, despite lower collaboration revenue. Phase 1 trial milestone achieved with FHD-909.

#FHTX Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

www.stocktitan.net/news/FHTX/foghorn-therap...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks with declining money flow, Tue Feb 4th - #UPB #SLDP #RZLV #PRME #MBRX #KITT #IRD #FHTX #DSGR #CELU #BLDE #ACHL #STEM #NRGV #KNOP #GWH #EQC #CANG #BKT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Foghorn Therapeutics Advances Cancer Drug Pipeline, Secures Runway into 2027 with $243.8M Cash Foghorn's FHD-909 progresses in Phase 1 for SMARCA4 mutated lung cancer, while achieving ARID1B degradation milestone. Strong financial position supports development through 2027.

#FHTX Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

www.stocktitan.net/news/FHTX/foghorn-therap...

StockTitan

@stocktitan.net

1 year ago

Foghorn Therapeutics Halts Key AML Drug Development After Phase 1 Results Fall Short Foghorn discontinues FHD-286 AML program after insufficient response rates, pivots focus to Lilly collaboration and FHD-909 development with $267.4M cash runway into 2027.

#FHTX Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

www.stocktitan.net/news/FHTX/foghorn-therap...

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #FHTX ) (FHTX) Investment Report

#StockMarket #News